Safety and patient experience with at-home infusion of ocrelizumab for multiple sclerosis.

ABSTRACT:

Objective

This study aimed to evaluate safety (infusion-related reactions [IRRs]) and patient satisfaction (patient-reported outcomes [PROs]) for at-home ocrelizumab administration for patients with multiple sclerosis (MS).

Methods

This open-label study included adult patients with an MS diagnosis who had completed a ≥ 600-mg ocrelizumab dose, had a patient-determined disease steps score of 0 to 6 and had completed PROs. Eligible patients received a 600-mg ocrelizumab home-based infusion over 2 h, followed by 24-h and 2-week post-infusion follow-up calls. IRRs and adverse events (AEs) were documented during infusions and follow-up calls. PROs were completed before and 2 weeks post infusion.

Results

Overall, 99 of 100 expected patients were included (mean [SD] age, 42.

SUBMITTER: Barrera B 

PROVIDER: S-EPMC10109340 | biostudies-literature | 2023 Apr

REPOSITORIES: biostudies-literature